Targeted Oncology Staff

During a Targeted Oncology case-based roundtable event, Benjamin Levy, MD, discussed the current targeted treatment options that target lung cancers that are positive for ALK rearrangements.

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, PhD, discussed with participants the adverse event management and expected efficacy of mobocertinib for patients with non–small cell lung cancer and an EGFR exon 20 insertion. This is the second of 2 articles based on this event.

Here is a look back at the FDA happenings from the month of November 2022.

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the data behind tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm. This is the second of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Atish D. Choudhury, MD, PhD, discussed with participants the use of cabazitaxel in a patient with metastatic castration-resistant prostate cancer who did not tolerate docetaxel.

At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.

During a Targeted Oncology case-based roundtable event, Daniel Petrylak, MD, discussed with participants the case of a patient with bladder cancer who has lung metastases and significant pulmonary comorbidities.

During a Targeted Oncology case-based roundtable event, Panayiotis S. Savvides, MD, PhD, MPH, discussed with participants their experiences using hedgehog pathway inhibitors and immunotherapy for patients with basal cell carcinoma.

During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed 3-year data on overall survival and subgroup analysis for the CheckMate 9LA trial of ipilimumab, nivolumab, and 2 cycles of chemotherapy.

During a Targeted Oncology case-based roundtable event, Kristen M. Pettit, MD, discussed with participants the case of a patient with high-risk primary myelofibrosis and significant cytopenias.

During a Targeted Oncology case-based roundtable event, Yousef Zakharia, MD, discussed new data supporting later-line options for patients with metastatic castration-resistant prostate cancer.

During a Targeted Oncology case-based roundtable event, Eric Jonasch, MD, discussed the efficacy of the CheckMate 9ER regimen for patients with renal cell carcinoma.

During a Targeted Oncology case-based roundtable event, May Cho, MD, discussed with participants how their practice is impacted by the introduction of trastuzumab deruxtecan for HER2+ gastric cancer.

During a Targeted Oncology case-based roundtable event, Ritu Salani, MD, MBA, discussed multiple studies that back up the use of PARP inhibition as a first-line maintenance therapy for patients with advanced ovarian cancer.

During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.

During a Targeted Oncology case-based roundtable event, Pedro Barata, MD, MSc, discussed with participants their approaches to therapy for a patient whose bladder cancer progresses after receiving chemotherapy and immunotherapy.

During a Targeted Oncology case-based roundtable event, Eric S. Nadler, MD, MPP, discussed the data supporting the use of targeted therapy for patients with non–small cell lung cancer and an EGFR exon 20 insertion.

During a Targeted Oncology case-based roundtable event, Jeanne M. Palmer, MD, discussed with participants how the approval of pacritinib for patients with myelofibrosis affects their treatment approach.

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Gregory Riely, MD, discussed the case of a patient with advanced non–small cell lung cancer who had an EGFR exon 20 insertion. This is the first of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.

At a live event discussing the case of a man, aged 75 years, with metastatic castration-resistant prostate cancer, Rana McKay, MD, focused on the makeup and results of the pivotal phase 4 CARD and phase 3 VISION studies.

During a Targeted Oncology case-based roundtable event, Jeffrey E. Lancet, MD, discussed the clinical presentation of blastic plasmacytoid dendritic cell neoplasm and how it came to be recognized as a distinct rare hematologic malignancy. This is the first of 2 articles based on this event.

During a Targeted Oncology case-based roundtable event, Joel Neal, MD, PhD, and Leah Backhus, MD, MPH, discussed adjuvant therapies including chemotherapy, immunotherapy, and targeted therapy for patients with non–small cell lung cancer.

During a Targeted Oncology case-based roundtable event, Sabarish Ayyappan, MD, discussed with participants which therapy would be appropriate for an older patient with relapsed/refractory diffuse large B-cell lymphoma.

During a Targeted Oncology case-based roundtable event, Raajit K. Rampal, MD, PhD, discussed recommendations and data on the use of JAK inhibitors to treat patients with myelofibrosis.

During a Targeted Oncology case-based roundtable event, Bradley J. Monk, MD, discussed recommendations for managing toxicity and dosing of PARP inhibitors as primary maintenance for ovarian cancer.

Retrospective analysis of a phase 2 trial indicated that tivozanib demonstrated efficacy and tolerability in the subset of patients who had non-clear cell histologies of renal cell carcinoma.